3 oversold ASX shares begging to rebound

Analysts think these shares are too cheap to ignore at current levels.

| More on:

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

The market has been serving up a fair amount of volatility lately, and in the rush to de-risk portfolios, even some of the highest quality ASX shares have been dragged lower.

But as history often shows, those moments of panic can create some of the most compelling buying opportunities — particularly when great businesses are oversold.

With that in mind, here are three ASX shares that look like they've been sold off too far, too fast — and may just be begging for a rebound according to analysts.

CSL Ltd (ASX: CSL)

CSL has been something of a quiet achiever over the years, compounding patient investors' capital at a steady pace. But lately, the biotech giant has been caught in the crosshairs of market pessimism — down significantly from its all-time highs.

The company is still generating billions in revenue, reinvesting heavily into R&D, and maintaining its global leadership in blood plasma therapies, vaccines, and kidney disease treatments. Yet the market has been pricing CSL as if its growth has permanently stalled — despite the fact that its plasma business is expected to underpin double-digit annual earnings growth in the coming years.

Goldman Sachs thinks investors should be snapping up CSL shares while they can. It recently put a buy rating and $307.30 price target on them.

Pro Medicus Ltd (ASX: PME)

High growth. High margins. Low churn. A dominant tech product in the US healthcare market. On paper, Pro Medicus should be an ASX share investor's dream.

But after hitting a high-flying valuation earlier this year, its shares have pulled back more than 30% — despite no meaningful deterioration in the business itself. Its Visage imaging platform continues to expand into major US hospital networks, and its pipeline remains as strong as ever. In fact, the company recently announced new AI research collaborations and continues to post impressive contract wins.

This kind of valuation reset without a drop in quality rarely lasts. Pro Medicus may have been caught up in the broader tech selloff, but it's hard to argue its fundamentals warrant the magnitude of the decline.

Bell Potter is a fan and recently put a buy rating and $280.00 price target on its shares.

WiseTech Global Ltd (ASX: WTC)

Finally, WiseTech is another ASX share that has taken a hit this year. Though, this is not just from tech sector weakness, but also from governance noise and some delayed product timelines. That said, the dust is beginning to settle — and beneath it is still one of Australia's most impressive tech stories.

The CargoWise platform is entrenched with global logistics players, boasting long-term contracts and 95% recurring revenue. While recent share price pressure has left investors a little bruised, it has also resulted in WiseTech trading at a multiple well below its historic average, even as growth continues at a solid clip.

Goldman Sachs is also a fan of WiseTech Global and has a buy rating and $84.45 price target on its shares.

Motley Fool contributor James Mickleboro has positions in CSL, Pro Medicus, and WiseTech Global. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Goldman Sachs Group, and WiseTech Global. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended WiseTech Global. The Motley Fool Australia has recommended CSL and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Cheap Shares

Cheap Shares

This leading fund manager is bullish on these 2 exciting ASX stocks

Here’s why these businesses could deliver strong returns.

Read more »

Two smiling work colleagues discuss an investment or business plan at their office.
Cheap Shares

3 oversold ASX 200 shares that could bounce back

Brokers think these shares are dirt cheap at current levels and could bounce back strongly.

Read more »

A female executive smiles as she carries out business on her mobile phone.
Cheap Shares

Why I think these 2 ASX shares are bargain buys

These businesses have a lot going for them.

Read more »

A man reacts with surprise when her see a bargain price on his phone.
Cheap Shares

I think these 2 cheap ASX shares are buys for value investors in June

These stocks may be priced too cheaply.

Read more »

Couple looking at their phone surprised, symbolising a bargain buy.
Cheap Shares

Why I think these 2 ASX shares are steals

These investments are trading at really attractive valuations.

Read more »

Image from either construction, mining or the oil industry of a friendly worker.
Cheap Shares

Buy these 2 impressive ASX shares in June: experts

Experts are fans of these businesses. Here’s why.

Read more »

Broker working with share prices on computers.
Cheap Shares

Why UBS thinks Magellan shares could deliver a 15% return in the next year

The broker is excited about this stock.

Read more »

Happy work colleagues give each other a fist pump.
Cheap Shares

Morgans names 2 cheap ASX 200 shares to buy

The leading broker thinks these shares are being undervalued by the market.

Read more »